Fournier’s gangrene is a newly identified safety concern in patients receiving sodium-glucose cotransporter 2 (SGLT2) inhibitors. Physicians prescribing these agents should be aware of this possible complication and have a high index of suspicion to recognise it in its early stages.

Indicated for the treatment of type 2 diabetes, SGLT2 inhibitors and the increased risk of Fournier’s gangrene have made international news.

Please sign in to read more